Summary KL-6, one of the MUC1 antigens, is a mucin-like high-molecular-weight glycoprotein, which is strongly expressed on type II pneumocytes. Serum levels of KL-6 have been shown to correlate with activity of interstitial pneumonia (IP). During embryonic development, MUC1 expression coincides with the onset of epithelial sheet and glandular formation. To investigate the potential role of KL-6 in lung morphogenesis, we examined KL-6 expression by immunohistochemistry on autopsied lung tissue specimens of 35 neonates and infants with gestational age from 23 to 40 weeks. Hyaline membranes (HMs) were detected in 13 of 35 cases. Simultaneously, antibody against surfactant protein A (SP-A) was employed in the study which is a distinct marker for type II pneumocytes. In all cases studied with gestational age above 23 weeks, staining for KL-6 was strongly positive in alveolar epithelial cells and in HMs found in 13 cases, whereas immunoreaction for PE10 varied depending on gestational age and duration of postnatal survival. Our findings suggest that KL-6 is expressed earlier in premature lung and may act as an important factor contributing to morphogenesis and function of developing lung in early gestation. r
Introduction
KL-6 is a mucin-like high-molecular-weight glycoprotein and is classified as a human MUC1 mucin. 1, 2 MUC1 is one of the mucins, which is densely expressed on the cell surface of most cancers of epithelial origin and also expressed at the secretory border of normal respiratory, gastrointestinal and genitorurinary epithelial tissues. Transfection studies have revealed that MUC1 participates in many biological functions, including anti-adhesion activity, [3] [4] [5] immunosuppressive activity, 6 and as a ligand for selectins. 7 During human and mouse embryonic developments, MUC1/Muc1 expression was found to coincide with epithelial sheet and glandular formation. [8] [9] [10] In all cases, during development in the mammary and salivary glands and in the lungs, pancreas, stomach and kidney, the induction of Muc-1 gene transcription preceded the functional activity of these organs. 8, 11 KL-6 was originally discovered as a circulating pulmonary adenocarcinoma-associated antigen. Of note, however, was the finding of an abnormally increased level of KL-6 in sera of patients with interstitial pneumonia (IP), especially IP in active condition. 12 Moreover, the clinical usefulness of KL-6 as a marker of disease activity of IP has been shown to be superior to that of other serum markers such as lactate dehydrogenase (LDH), type-III procollagen N-terminal peptide and Creactive protein.
12,13 KL-6 is thus a useful marker of disease activity for IP and a serum diagnostic marker for IP. However, expression of KL-6 during embryonic development has not yet been documented.
Our previous study demonstrated that in various kinds of IP, intense staining for KL-6 and surfactant protein A (SP-A) was detected in the proliferating type II pneumocytes as well as in hyaline membrane (HM), a frequent phenomenon in the acute stage of IP. SP-A is the major protein component of pulmonary surfactant synthesized and secreted by type II pneumocytes. The appearance of SP-A reflects the functional ability of alveolar cells. To investigate the potential role of KL-6 in lung morphogenesis and whether it appears prior to the functional activity of SP-A secretion, we examined KL-6 and SP-A expression by immunohistochemical staining of postmortem lung specimens from neonates and infants of 23-40 weeks' gestational age.
Materials and methods
Lung tissue specimens of 35 neonates and infants were obtained from autopsy at the Department of Pathology of Kochi Medical School, Kochi, Japan. The gestational age of the 35 cases ranged from 23 to 40 weeks, and details of postnatal survival are shown in Table 1 . Most of the cases died of cerebroventricular abnormalities and/or pulmonary immaturity within 1 day after birth. These immaturities were proportional to gestational ages, but not hypoplasia. In the cases with 23-27 weeks' gestation, very preterm infants had body weights of 0.3-0.9 kg. Chromosomal anomalies were demonstrated in five cases. Based on the presence of HM on histopathological examination, HM disease was diagnosed in 13 cases (Table 1 ). The ethics committee of Kochi Medical School, Kochi, Japan approved this study, the relatives of all patients having provided written, informed consent before enrolment.
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Tissue slices were fixed in 20% phosphatebuffered formalin and embedded in paraffin and sectioned at 3 mm for histological and immunohistochemical evaluation. Immunohistochemical stains were performed using the avidin-biotin peroxidase complex (ABC) method (LSAB kit, Dako, Carpinteria, CA, USA) with antibodies against KL-6 (10 ng/ml, from Dr. N. Kohno), surfactant protein A (PE10; Dako; dilution, 1:100), epithelial membrane antigen (EMA; Dako; dilution, 1:50), factor VIIIrelated antigen (Factor VIII; Dako; dilution, 1:400), human urinary protein-1 (Hup-1; Dako; dilution, 1:100), pancytokeratin (AE1/AE3; Boehringer-Mannheim, Indianapolis, IN, USA; dilution, 1:400), and cytokeratin 19 (ScyTek Laboratories, Logan, Utah, USA; dilution, 1:30). Antigen retrievals using 0.1% pronase digestion or microwave pretreatment were performed for antibodies to factor VIII, AE1/AE3 and CK19. Appropriate positive and negative controls were stained in parallel. Staining procedures were performed according to the manufacturers' instructions.
Results
The major results of immunohistochemical studies of KL-6 and SP-A are shown in Table 1 . KL-6 expression was conspicuous in the alveolar and bronchiolar epithelial cells in all the cases studied with gestational age from 23 to 40 weeks (Figs. 1B,  2A, 3A) , and was also discernible in HMs found in 13 cases. However, PE10, a distinct marker for type II pneumocytes, exhibited quite diverse immunoreactivity depending on gestational age and duration of postnatal survival. In cases with less than 28 weeks' gestational age, no staining for PE10 was detected in the alveolar epithelial cells (Fig. 1C) or in HMs except in four with prolonged postnatal survival (case nos. 5, 9, 11, and 12) (Fig. 2B) . Case no. 5 with 24 weeks' gestational age and 226 days postnatal survival expressed PE10 in both alveolar cells and HMs. Notably, reactivity for PE10 was initially demonstrated as granular material in the alveolar spaces of the lower respiratory tract (Fig.  2B) . From 28 weeks' to 31 weeks' gestational age, cases exhibited transitional immunostaining for PE10 between negativity and positivity. After that, in the cases with >31 weeks' gestational age, PE10 labeling was predominant in the alveolar epithelial cells (Fig. 3B) , and was also present in HMs. In cases positive for both KL-6 and PE10, the intensity of PE10 staining was stronger than that for KL-6. KL-6-positive reaction was observed in vascular endothelium (Fig. 1B, arrows, 2B, arrows) . In addition, in all cases tested, stainings for epithelial markers such as EMA, AE1/AE3 and CK19 were present in the alveolar and bronchiolar epithelial cells, and Factor VIII was detected in endothelial cells. However, their immunoreactivities in HMs varied in different regions of the same case, similar to adult IP. Likewise, Hup-1, a specific marker for Clara cell protein, was indefinitely expressed on HMs, although Clara cells were widely positive.
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Discussion
In this study, we found KL-6 expression by immunohistochemical staining in lung tissues from neonates and infants with gestational ages of 23 to 40 weeks. The immunoreactivities observed demonstrate that expression of KL-6 appears early in premature lung, which precedes its functional activity of SP-A secretion, strongly suggesting that KL-6 plays an important role in lung morphogenesis in early gestation.
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KL-6 was first described by Kohno and coworkers. 1 Because it bears a sialylated carbohydrate, KL-6 was later termed MUC1.
2 KL-6 expression is dramatically increased in atypical and/or regenerating type II pneumocytes in tissues from patients with IP. 12 Clinical studies have shown that serum level of KL-6 is elevated in more than 70% of patients with IP, such as idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, radiation pneumonitis, pulmonary sarcoidosis and collagen vascular disease-associated interstitial pneumonitis. 12, [13] [14] [15] Moreover, levels of KL-6 are significantly higher in patients with active disease than in those with inactive disease.
12-15 KL-6 has thus been identified as a serum diagnostic marker for IP. Here we demonstrate strong immunostaining for KL-6 in the alveolar and bronchiolar epithelial cells in cases with gestational age above 23 weeks. The results of the present study expand previous observations on KL-6 and provide the first evidence of KL-6 expression in premature lung. Significantly, expression of KL-6 in alveolar cells was in this study much earlier than that of SP-A, which is synthesized and secreted by type II pneumocytes, suggesting that KL-6 expression in the alveolar cells is prior to their functional activity. KL-6 now termed MUC1, has been reported to play a role in morphogenesis. 8, 11, 16 In the developing mouse embryo, Muc1 protein and mRNA appearance was found to be coincident with epithelial sheets and glandular formation. 8 Moreover, the induction of Muc-1 gene transcription preceded the functional activity of the organs known to express it. 8, 11 It has been shown that MUC1 mucin is a potent glandular morphogen. 16 However, Muc-1 null mice developed normally and remained healthy and fertile. 17 Muc-1 deficient mice exhibited no differences in survival rate and appeared phenotypically normal in all respects. The authors hypothesized that other mucins and mucin-like genes might compensate for Muc-1 deficiency. 17 In the yeast Saccharomyces cerevisiae, deletion of MUC1 abolished pseudohyphal differentiation and invasive growth. 18, 19 Furthermore, MUC1 is overexpressed in carcinomas and has been implicatied in tumor progression and metastasis, resulting in a less differentiated phenotype and a poor prognosis. [20] [21] [22] This could be attributed to anti-adhesion properties of MUC1, including inhibiting cell-cell and cell-extracellular matrix (ECM) interactions, decreasing cell aggregation, and repressing E-cadherin-mediated cell-cell adhesion and intergrin-mediated cell-ECM adhesion. [3] [4] [5] Of note, KL-6 was found to be chemotactic for human fibroblasts. 23 Fibroblasts contribute to the synthesis of the insulin-like growth factors (IGFs), which are implicated in regulation of embryonic and fetal growth and development. [24] [25] [26] Expression of KL-6 in early gestation (from at least 23 weeks' gestation) may therefore support the hypothesis of its essential roles in morphogenesis and lung development.
It is important to note that immunostaining for KL-6 and SP-A was dissociated in this study, although both could be detected in type II pneumocytes. We have shown that SP-A production depends on gestational age and longevity of postnatal life. Except in cases with long postnatal life, before 28 weeks' gestation SP-A cannot be expressed in alveolar cells although KL-6 can. SP-A expression was first discernible in week 28 of gestation and was detectable from 32 weeks' gestation. Our finding of the appearance of SP-A by 28 weeks' gestation accords with that of initiation of transcription of the SP-A gene in fetal lung after approx. 70% of gestation is completed, 27 and further clarifies the time of SP-A expression in fetal lung. Interestingly, four specific cases (o28 week gestational age) with prolonged postnatal survival in our study exhibited SP-A expression in the alveolar cells as well as in HMs. Since atmospheric oxygen stimulates SP-A gene expression and morphologic development, 28 we reasoned that postnatal life contributes to the synthesis of SP-A in prematurely born infants.
We found as well that in cases with lack of SP-A expression in alveolar cells, SP-A was also not detected in HMs. After SP-A expression was initiated in the alveolar cells, reaction for SP-A was noted in HMs. This finding suggests that SP-A is not an essential component of HM and that its involvement in HM formation should be related to the responsiveness of lung resulting from its maintaining low alveolar surface tension. In contrast, KL-6 expression was demonstrated in HMs found in 13 cases, indicating that KL-6 is the primary component of HM.
One intriguing, and potentially useful, finding of the present study is that vascular endothelium exhibits KL-6 expression in some areas. In most patients with IP, significantly increased levels of KL-6 have been detected in sera, [12] [13] [14] [15] as in bronchoalveolar lavage fluid (BALF) and epithelial lining fluid (ELF). 9, 16 In conclusion, this study provides a novel insight into understanding KL-6, showing that it is expressed early even in very premature lung at above 23 weeks' gestation. In particular, we have demonstrated that SP-A is not an essential component of
